Celldex reports positive phase 1 results for bispecific antibody CDX-622

June 14, 2026 5:15 AM

Celldex Therapeutics (NASDAQ: CLDX) presented results from a phase 1 study of CDX-622, a bispecific antibody targeting soluble stem cell ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found